GLP-1 and GIP/GLP-1 Receptor Agonists Weight Management

Products grouped by FDA-approved indication and active ingredient. Last updated 2/2024.
Semaglutide (GLP-1 Receptor Agonist)

Wegovy Weight Management 10-15% SUBQ Once-Weekly

Type 2 Diabetes Dosing and Titration for Weight Management in Adults & Pediatrics Ages 12+ Years

Initiation and Escalation:

Semaglutide (GLP-1 Receptor Agonist) Dulaglutide (GLP-1 Receptor Agonist) Start at 0.25 mg/week for 4 weeks (“Weeks 1 to 4”)
↑ to 0.5 mg/week for 4 weeks (“Weeks 5 to 8”)
Ozempic Type 2 Diabetes ●●●● SUBQ Once-Weekly Trulicity Type 2 Diabetes ●●●● SUBQ Once-Weekly Then ↑ to 1 mg/week for 4 weeks (“Weeks 9 to 12”)
Then ↑ to 1.7 mg/week for 4 weeks (“Weeks 13 to 16”)
If an escalation dose is not tolerated, consider delaying escalation 4 weeks
Dosing and Titration for T2DM in Adults Dosing and Titration for T2DM in Adults and Pediatrics Ages 10+ Years Maintenance (Adults):
Either ↑ to 2.4 mg/week (recommended) or remain at 1.7 mg/week
Start at 0.25 mg/week for 4 weeks, then increase to 0.5 mg/week Start at 0.75 mg/week based on treatment response/tolerability for “Week 17 and onwards”
For added glycemic control, may ↑ to 1 mg/week after ≥4 weeks For added glycemic control, may ↑ to 1.5 mg/week after ≥4 weeks* Maintenance (Ages 12-17 Years):
For added glycemic control, may ↑ to 2 mg/week after ≥4 weeks
Adults Only: ↑ to 2.4 mg/week for “Week 17 and onwards”;
For added glycemic control, may ↑ to 3 mg/week after ≥4 weeks May reduce to 1.7 mg/week if 2.4 mg/week is not tolerated
Discontinue if 1.7 mg is not tolerated
For added glycemic control, may ↑ to 4.5 mg/week after ≥4 weeks
0.25 or 0.5 mg per injection
(2 mg/3 mL) *In adults, the FDA prescribing information does not explicitly specify a titration
(once-weekly dosing)
duration between increasing from the 0.75 mg/week dose to the 1.5 mg/week dose

(0.25 mg/0.5 mL)

0.25 mg, single dose
1 mg per injection (once-weekly dosing)
(4 mg/3 mL) (once-weekly dosing)
(0.75 mg/0.5 mL) 0.75 mg, single dose
(once-weekly dosing) 0.5 mg, single dose
(0.5 mg/0.5 mL)
(once-weekly dosing)
(8 mg/3 mL) 2 mg per injection
(once-weekly dosing) (1.5 mg/0.5 mL) 1.5 mg, single dose
(once-weekly dosing) 1 mg, single dose
(1 mg/0.5 mL)
(once-weekly dosing)
3 mg, single dose
Rybelsus Type 2 Diabetes ●●● Oral Once-Daily (3 mg/0.5 mL)
(once-weekly dosing) 1.7 mg, single dose
(1.7 mg/0.75 mL)
(once-weekly dosing)

Dosing and Titration for T2DM in Adults (4.5 mg/0.5 mL) 4.5 mg, single dose
(once-weekly dosing) 2.4 mg, single dose
(2.4 mg/0.75 mL)
Start at 3 mg/day for 30 days, then increase to 7 mg/day (once-weekly dosing)
For added glycemic control, may ↑ to 14 mg/day* after ≥30 days
*The FDA prescribing information recommends against using two 7 mg tablets
to achieve 14 mg dose Liraglutide (GLP-1 Receptor Agonist)
Tirzepatide (GIP/GLP-1 Receptor Agonist)
14 mg tablet Victoza Type 2 Diabetes ●● SUBQ Once-Daily
3 mg tablet
(once-daily)
7 mg tablet
(once-daily) (once-daily) Zepbound Weight Management 12-20% SUBQ Once-Weekly

Dosing and Titration for T2DM in Adults & Pediatrics Ages 10+ Years
Dosing and Titration for Weight Management in Adults
Tirzepatide (GIP/GLP-1 Receptor Agonist) Adults:
Start at 2.5 mg/week for 4 weeks, then ↑ to 5 mg/week
Start at 0.6 mg/day for 1 week, then ↑ to 1.2 mg/day
For added glycemic control, may ↑ to 1.8 mg/day after ≥1 week Dose may be ↑ in 2.5 mg increments after ≥4 week on current dose

Mounjaro Type 2 Diabetes ●●●●● SUBQ Once-Weekly

Ages 10-17 Years:
Recommended maintenance dosages are 5, 10, or 15 mg/week
Consider treatment response/tolerability with maintenance dose selection;
Start at 0.6 mg/day If a recommended maintenance dose is not tolerated, consider lower dose
For added glycemic control, may ↑ to 1.2 mg/day after ≥1 week
Dosing and Titration for T2DM in Adults
For added glycemic control, may ↑ to 1.8 mg/day after ≥1 week
Start at 2.5 mg/week for 4 weeks, then ↑ to 5 mg/week (2.5 mg/0.5 mL)
2.5 mg, single dose
For added glycemic control, may ↑ to 7.5 mg/week after ≥4 week (once-weekly dosing)
For added glycemic control, may ↑ to 10 mg/week after ≥4 week 0.6 mg, 1.2 mg, or 1.8 mg per
(18 mg/3 mL)
For added glycemic control, may ↑ to 12.5 mg/week after ≥4 week injection (once-daily dosing)
(5 mg/0.5 mL) 5 mg, single dose
For added glycemic control, may ↑ to 15 mg/week after ≥4 week (once-weekly dosing)
After initial use, pen can be stored for 30 days at ≤86°F (30°C); do not freeze

(2.5 mg/0.5 mL)

2.5 mg, single dose (7.5 mg/0.5 mL)
7.5 mg, single dose
(once-weekly dosing) Exenatide (GLP-1 Receptor Agonist) (once-weekly dosing)

5 mg, single dose

(5 mg/0.5 mL)
(once-weekly dosing) Byetta Type 2 Diabetes ●● SUBQ Twice-Daily (10 mg/0.5 mL) 10 mg, single dose
(once-weekly dosing)

(7.5 mg/0.5 mL)

7.5 mg, single dose Dosing and Titration for T2DM in Adults 12.5 mg, single dose
(once-weekly dosing) (12.5 mg/0.5 mL)
(once-weekly dosing)
Start at 5 mcg twice per day (BID)
For added glycemic control, may ↑ to 10 mcg BID after ≥1 month
(10 mg/0.5 mL) 10 mg, single dose 15 mg, single dose
(once-weekly dosing) (15 mg/0.5 mL)
(once-weekly dosing)
(300 mcg/1.2 mL)
5 mcg per injection
(twice-daily dosing)
(12.5 mg/0.5 mL)
12.5 mg, single dose
(once-weekly dosing)
10 mcg per injection Liraglutide (GLP-1 Receptor Agonist)
(600 mcg/2.4 mL)
(twice-daily dosing)
15 mg, single dose
(15 mg/0.5 mL)
(once-weekly dosing) After initial use, pen can be stored for 30 days at ≤77° (25°C); do not freeze Saxenda Weight Management 5-7% SUBQ Once-Daily

Note: Mounarjo is also available as single-use vials

Dosing and Titration for Weight Management in Adults & Pediatrics Ages 12+ Years
Bydureon BCise Type 2 Diabetes ●● SUBQ Once-Weekly
Initiation and Escalation:

KEY Start at 0.6 mg/day for 1 week (“Week 1”)

Dosing and Titration for T2DM in Adults and Pediatrics Ages 10+ Years ↑ to 1.2 mg/day for 1 week (“Week 2”)
●●●●● Relative A1c-lowering efficacy: Based on information from clinical trials Then ↑ to 1.8 mg/day for 1 week (“Week 3”)
and the ADA Standards of Care. Individual response may vary. Recommended dose is 2 mg/week Then ↑ to 2.4 mg/day for 1 week (“Week 4”)
Typical reduction in total body weight (%): Based on data from clinical If an escalation dose is not tolerated, consider delaying escalation ~1 week
% trials; Saxenda (liraglutide) assessed over a 56-week period, Wegovy
(semaglutide) assessed over a 68-week period, and Zepbound (tirzepatide) Maintenance (Adults):
(2 mg/0.85 mL) 2 mg, single dose
assessed over a 72-week period. Individual response may vary. ↑ to 3 mg/day for “Week 5 and onwards”;
(once-weekly dosing)
Discontinue if 3 mg is not tolerated
Needles must be prescribed separately along with the pen.
Maintenance (Ages 12-17 Years):
↑ to 3 mg/day for “Week 5 and onwards”;
May reduce to 2.4 mg/day if 3 mg/day is not tolerated;
Discontinue if 2.4 mg is not tolerated

0.6 mg, 1.2 mg, 1.8 mg,

(18 mg/3 mL) 2.4 mg, or 3 mg per injection
(once-daily dosing)

After initial use, pen can be stored for 30 days at ≤86° (30°C); do not freeze

More clinical pearls at pyrls.com ® 2024 Cosmas Health, Inc. and/or its affiliates. All rights reserved.